TY - JOUR
T1 - NCCN GUIDELINES® INSIGHTS
T2 - Rectal Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines
AU - Benson, Al B.
AU - Venook, Alan P.
AU - Adam, Mohamed
AU - Chang, George
AU - Chen, Yi Jen
AU - Ciombor, Kristen K.
AU - Cohen, Stacey A.
AU - Cooper, Harry S.
AU - Deming, Dustin
AU - Garrido-Laguna, Ignacio
AU - Grem, Jean L.
AU - Haste, Paul
AU - Hecht, J. Randolph
AU - Hoffe, Sarah
AU - Hunt, Steven
AU - Hussan, Hisham
AU - Johung, Kimberly L.
AU - Joseph, Nora
AU - Kirilcuk, Natalie
AU - Krishnamurthi, Smitha
AU - Malla, Midhun
AU - Maratt, Jennifer K.
AU - Messersmith, Wells A.
AU - Meyerhardt, Jeffrey
AU - Miller, Eric D.
AU - Mulcahy, Mary F.
AU - Nurkin, Steven
AU - Parikh, Aparna
AU - Patel, Hitendra
AU - Pedersen, Katrina
AU - Saltz, Leonard
AU - Schneider, Charles
AU - Shibata, David
AU - Shogan, Benjamin
AU - Skibber, John M.
AU - Sofocleous, Constantinos T.
AU - Tavakkoli, Anna
AU - Willett, Christopher G.
AU - Wu, Christina
AU - Jones, Frankie
AU - Gurski, Lisa
N1 - Publisher Copyright:
© JNCCN—Journal of the National Comprehensive Cancer Network.
PY - 2024/8/1
Y1 - 2024/8/1
N2 - The determination of an optimal treatment plan for an individual patient with rectal cancer is a complex process. In addition to decisions relating to the intent of rectal cancer surgery (ie, curative or palliative), consideration must also be given to the likely functional results of treatment, including the probability of maintaining or restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly for patients with distal rectal cancer, finding a balance between curative-intent therapy while having minimal impact on quality of life can be challenging. Furthermore, the risk of pelvic recurrence is higher in patients with rectal cancer compared with those with colon cancer, and locally recurrent rectal cancer is associated with a poor prognosis. Careful patient selection and the use of sequenced multimodality therapy following a multidisciplinary approach is recommended. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a “watch-and-wait” nonoperative management approach for clinical complete responders to neoadjuvant therapy.
AB - The determination of an optimal treatment plan for an individual patient with rectal cancer is a complex process. In addition to decisions relating to the intent of rectal cancer surgery (ie, curative or palliative), consideration must also be given to the likely functional results of treatment, including the probability of maintaining or restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly for patients with distal rectal cancer, finding a balance between curative-intent therapy while having minimal impact on quality of life can be challenging. Furthermore, the risk of pelvic recurrence is higher in patients with rectal cancer compared with those with colon cancer, and locally recurrent rectal cancer is associated with a poor prognosis. Careful patient selection and the use of sequenced multimodality therapy following a multidisciplinary approach is recommended. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a “watch-and-wait” nonoperative management approach for clinical complete responders to neoadjuvant therapy.
KW - Combined Modality Therapy/methods
KW - Humans
KW - Medical Oncology/standards
KW - Neoadjuvant Therapy/methods
KW - Neoplasm Staging
KW - Rectal Neoplasms/therapy
UR - http://www.scopus.com/inward/record.url?scp=85201581961&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2024.0041
DO - 10.6004/jnccn.2024.0041
M3 - Article
C2 - 39151454
AN - SCOPUS:85201581961
SN - 1540-1405
VL - 22
SP - 366
EP - 375
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 6
ER -